WINNIPEG, Manitoba - (April 6, 2004) - Medicure
Inc. (TSX: MPH/Amex: MCU), a cardiovascular drug discovery and development
company will host a Conference Call on Wednesday, April 7, 2004,
to discuss its Phase II trial as part of its development program
for MC-4232.
A News Release regarding the Phase II trial and the development
program will be issued prior to the opening of the markets on April
7, 2004, with the Conference Call taking place at 11 a.m. Eastern
Daylight Time.
SUMMARY
Title of Conference: Medicure Hypertension Trial Update
Date of Conference Call: Wednesday, April 7, 2004
Time of Call: 11 a.m. Eastern Daylight Time
Dial-in Numbers for 1-877-461-2814 (Toll Free)
Participants 416-695-9753 (Toronto area participants)
Confirmation # for Call: T490260M
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia, ischemic
reperfusion injury, and stroke. The cardiovascular and stroke market
is the largest pharmaceutical sector with annual global sales of
over US $70 billion.
The Company's second product candidate, MC-4232, is being targeted
for the treatment of hypertension, a common disorder in which blood
pressure remains abnormally high. Approximately 73% of the more
than 50 million adult Americans who have hypertension, are not adequately
treated.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
